1 – 10 of 12
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML
(
- Contribution to journal › Article
- 2019
-
Mark
FLT3
N676K
drives acute myeloid leukemia in a xenograft model of KMT2A-MLLT3 leukemogenesis
(
- Contribution to journal › Letter
- 2018
-
Mark
CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting
(
- Contribution to journal › Article
- 2016
-
Mark
IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models
(
- Contribution to journal › Article
- 2015
-
Mark
IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome.
(
- Contribution to journal › Article
-
Mark
Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.
(
- Contribution to journal › Article
- 2014
-
Mark
Modeling chronic myeloid leukemia in immunodeficient mice reveals expansion of aberrant mast cells and accumulation of pre-B cells.
(
- Contribution to journal › Article
- 2013
-
Mark
Selective killing of candidate AML stem cells by antibody targeting of IL1RAP.
(
- Contribution to journal › Article
-
Mark
SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell function.
(
- Contribution to journal › Article
- 2010
-
Mark
Modeling the human 8p11-myeloproliferative syndrome in immunodeficient mice
(
- Contribution to journal › Article